Article thumbnail
Location of Repository

A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India

By Vidya Nand Rabi Das, Niyamat Ali Siddiqui, Krishna Pandey, Vijay Pratap Singh, Roshan K Topno, Dharmendra Singh, Rakesh Bihari Verma, Alok Ranjan, Prabhat Kumar Sinha and Pradeep Das
Topics: Original Research
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2004). A comparative evaluation of Amphotericin B and Sodium Antimony Gluconate, as fi rst line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol.
  2. (2001). A randomised clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis.
  3. (1998). A randomised comparison of classical mode of Amphotericin B with its newer modes of administration in Kala-azar.
  4. A single high dose treatment of Kala-azar with Ambisome (Amphotericin B Lipid complex): a pilot study.
  5. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg.
  6. (2004). Amphotericin B treatment for Indian Visceral Leishmaniasis: conventional verses lipid formulation. Clin Infect Dis.
  7. (2007). Amphotericin B treatment for Indian visceral leishmaniasis: Response to 15 daily versus alternate day infusions. Clin Infect Dis.
  8. Amphotericin versus sodium stibo-gluconate in fi rst line treatment of Indian Kala-azar.
  9. Amphoterocin B versus Pentamidine in antimony-unresponsive Kala-azar cases.
  10. (2001). Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother.
  11. (1991). Comparisons of regimens of treatment of resistant Kala-azar patients: A randomised study. Am J Trop Med Hyg.
  12. (1998). Do the diminishing effi cacy and increasing toxicity of SSG, in the treatment of Kala-azar in Bihar, India, justify its continued use. Ann Trop Med Parasitol.
  13. (2007). Drug policy for visceral Leishmaniasis: a cost effectiveness analysis. Trop Med Int Health.
  14. (2006). Drug resistance in leishmaniasis. Clin Microbiol Rev.
  15. (1983). Evaluation of Pentamidine isethionate in the treatment of Kala-azar occurring in North-Bihar, India. Trans R Soc Trop Med Hyg.
  16. (1993). Evaluation on Amphotericin B as a fi rst line drug in comparison to Stibo-Gluconate in the treatment of fresh cases of Kala-azar. Indian J Med Res.
  17. (2000). Failure of Pentavalent antimony in visceral leishmaniasis in India: report from the center of Indian epidemic. Clin Infect Dis.
  18. (1997). Human Leishmaniasis: clinical, diagnostic and chemotherapeutic development in the last 10 years. Clin Infect Dis.
  19. Magnitude of unresponsiveness to Sodium-Stibo-Gluconate in the treatment of visceral leishmaniasis in Bihar.
  20. Management of Kala-azar in India: Current Concepts.
  21. Oral miltefosine for Indian leishmaniasis.
  22. (2007). Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis.
  23. (1993). Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today.
  24. Recent understanding in the treatment of visceral leishmaniasis.
  25. (2005). Risk factors for Indian Kala-azar. Am J Trop Med Hyg.
  26. (2004). Successful treatment with amphotericin B of patients with visceral Leishmaniasis resistant to meglumine antimonite. Acta Medica Iranica.
  27. (1996). The re-emergence of visceral leishmaniasis in Brazil. Emerg Infect Dis.
  28. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal Amphotericin B: randomized trial.
  29. (1993). Treatment of Kala-azar during pregnancy.
  30. Treatment of visceral leishmaniasis (Kala-azar): a decade of progress and future approaches.
  31. (1994). Treatment of Visceral Leishmaniasis unresponsive to Pentamidine with Amphotericin B.
  32. (2005). Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet Infect Dis.
  33. Unresponsiveness in Indian Kala-azar.
  34. (1993). Visceral Leishmaniasis resistant to conventional treatments: value of Amphotericine B. Pathol Biol
  35. Visceral Leishmaniasis- current therapeutic modalities.
  36. (2002). Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.